Therefore, direct inhibition of NOTCH3 expression by KLF4 induction may be an effective therapeutic strategy for T‐ALL with either activating NOTCH3 mutations or NOTCH3 overexpression. The gene discussed is NOTCH3; the disease is acute lymphoblastic leukemia.